That’s usually the process with new cancer drugs. They start third or fourth or fifth line that aren’t always the first pathways chosen. So yes, it’s usually the sickest patients that start to get these drugs first. The good news is, we are in a very favorable position in my opinion to help many of these patients. So adding it to a SOC pathway that’s third or fourth line isn’t a bad option. Blow the doors off, and you move closer to the top of the pathways.